Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. Read more about Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.
Imaging biomarkers of TERT or GABPB1 silencing in TERT-positive glioblastoma. Read more about Imaging biomarkers of TERT or GABPB1 silencing in TERT-positive glioblastoma.
Molecularly determining cognition in glioma: New insights as the plot thickens. Read more about Molecularly determining cognition in glioma: New insights as the plot thickens.
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Read more about Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes. Read more about Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes.
OS07.6.A Extent of resection in glioblastoma: refinement and prognostic validation of a classification system from the RANO resect group. Read more about OS07.6.A Extent of resection in glioblastoma: refinement and prognostic validation of a classification system from the RANO resect group.
Building on the journal's success through collaboration and partnership. Read more about Building on the journal's success through collaboration and partnership.
PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications. Read more about PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.
Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study. Read more about Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.
A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act. Read more about A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act.
